-DOCSTART- -X- O
Human -X- _ B-Patient
metapneumovirus -X- _ I-Patient
( -X- _ I-Patient
hMPV -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
respiratory -X- _ O
virus -X- _ O
detected -X- _ O
in -X- _ O
≥9 -X- _ O
% -X- _ O
of -X- _ O
allogeneic -X- _ O
hematopoietic -X- _ O
stem -X- _ O
cell -X- _ O
transplant -X- _ O
( -X- _ O
HSCT -X- _ O
) -X- _ O
recipients -X- _ O
, -X- _ O
in -X- _ O
whom -X- _ O
it -X- _ O
can -X- _ O
cause -X- _ O
significant -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Given -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
effective -X- _ O
antivirals -X- _ O
, -X- _ O
we -X- _ O
investigated -X- _ O
the -X- _ O
potential -X- _ O
for -X- _ O
immunotherapeutic -X- _ B-Intervention
intervention -X- _ I-Intervention
, -X- _ O
using -X- _ O
adoptively -X- _ B-Intervention
transferred -X- _ I-Intervention
T -X- _ I-Intervention
cells. -X- _ I-Intervention
Thus -X- _ O
, -X- _ O
we -X- _ O
characterized -X- _ O
the -X- _ O
cellular -X- _ O
immune -X- _ O
response -X- _ O
to -X- _ O
the -X- _ O
virus -X- _ O
and -X- _ O
identified -X- _ O
F -X- _ B-Outcome
, -X- _ I-Outcome
N -X- _ I-Outcome
, -X- _ I-Outcome
M2-1 -X- _ I-Outcome
, -X- _ I-Outcome
M -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
P -X- _ I-Outcome
as -X- _ I-Outcome
immunodominant -X- _ I-Outcome
target -X- _ I-Outcome
antigens. -X- _ I-Outcome
Reactive -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
were -X- _ I-Outcome
polyclonal -X- _ I-Outcome
( -X- _ I-Outcome
ie -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
expressed -X- _ I-Outcome
CD4 -X- _ I-Outcome
and -X- _ I-Outcome
CD8 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
T-helper -X- _ I-Outcome
type -X- _ I-Outcome
1 -X- _ I-Outcome
polarized -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
polyfunctional -X- _ I-Outcome
( -X- _ I-Outcome
ie -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
produced -X- _ I-Outcome
interferon -X- _ I-Outcome
γ -X- _ I-Outcome
, -X- _ I-Outcome
tumor -X- _ I-Outcome
necrosis -X- _ I-Outcome
factor -X- _ I-Outcome
α -X- _ I-Outcome
, -X- _ I-Outcome
granulocyte-macrophage -X- _ I-Outcome
colony-stimulating -X- _ I-Outcome
factor -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
granzyme -X- _ I-Outcome
B -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
they -X- _ I-Outcome
were -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
kill -X- _ I-Outcome
autologous -X- _ I-Outcome
antigen-loaded -X- _ I-Outcome
targets. -X- _ I-Outcome
The -X- _ O
detection -X- _ O
of -X- _ O
hMPV-specific -X- _ O
T -X- _ O
cells -X- _ O
in -X- _ O
HSCT -X- _ O
recipients -X- _ O
who -X- _ O
endogenously -X- _ O
controlled -X- _ O
active -X- _ O
infections -X- _ O
support -X- _ O
the -X- _ O
clinical -X- _ O
importance -X- _ O
of -X- _ O
T-cell -X- _ O
immunity -X- _ O
in -X- _ O
mediating -X- _ O
protective -X- _ O
antiviral -X- _ O
effects. -X- _ O
Our -X- _ O
results -X- _ O
demonstrate -X- _ O
the -X- _ O
feasibility -X- _ O
of -X- _ O
developing -X- _ O
an -X- _ O
immunotherapy -X- _ O
for -X- _ O
immunocompromised -X- _ O
patients -X- _ O
with -X- _ O
uncontrolled -X- _ O
infections -X- _ O
. -X- _ O

